Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

Launched by AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO S.P.A · Jul 12, 2021

Keywords

ClinConnect Summary

The study aims to describe the current use of dalbavancin in diabetic patients suffering from infections proven or suspected to be caused by Gram-positive or mixed Gram-positive and Gram-negative bacteria (with dalbavancin chosen for treating the Gram-positive component) in Italy and Spain.

As overall strategies to reduce the risk of developing severe infections and poor treatment outcomes among diabetic patients are under-researched and should be explored. This study could increase the knowledge of infection management among diabetic patients treated with dalbavancin in order to support a...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years at the time of dalbavancin treatment initiation
• • Male and female patients
• • Patients who received dalbavancin as targeted or empirical therapy to treat Gram-positive bacterial infection or as anti-Gram-positive component of a treatment regimen for mixed infection (e.g., with concurrent antibacterial or antifungals drugs for covering Gram-negative strains or fungi)
• • Patients who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study
• • Patients with known type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) at the time of infectious disease of interest diagnosis
• • Patients with available retrospective data in medical charts, including information about dalbavancin treatment and diabetes history
• • Patients who gave informed consent and personal data processing consent to take part into the study following local regulation.
• Exclusion Criteria:
• • Patients enrolled in a clinical trial in which treatment with dalbavancin was managed through a study protocol
• • Patients diagnosed with any hyperglycemic state other than T1DM or T2DM at the time of dalbavancin treatment initiation
• • Patients with long-term infection (over than 12 months of duration) at the time of dalbavancin treatment initiation
• • Previous participation in this study. Participation is defined as having given informed consent in this study
• • Pregnant or breast-feeding patients from start time of dalbavancin treatment initiation till enrolment visit.